MCID: PRP019
MIFTS: 62

Peripheral Nervous System Disease

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Disease

MalaCards integrated aliases for Peripheral Nervous System Disease:

Name: Peripheral Nervous System Disease 12 15
Peripheral Neuropathy 12 76 54 29 6 73
Peripheral Nervous System Diseases 44
Peripheral Nerve Disorders 43
Peripheral Nerve Disease 12
Neuropathy, Peripheral 40

Classifications:



External Ids:

Disease Ontology 12 DOID:574
ICD10 33 G64
ICD9CM 35 350-359.99
MeSH 44 D010523
SNOMED-CT 68 42658009

Summaries for Peripheral Nervous System Disease

NINDS : 54 Peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system, which sends signals between the brain and spinal cord and all other parts of the body. Neuropathy means damage to one or more nerves, especially the peripheral nerves. More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms and prognosis. Impaired function and symptoms depend on the type of nerves that are damaged. Symptoms of neuropathy range from mild to disabling and may include a loss of reflexes, problems feeling pain or changes in temperature, numbness and tingling, and pain that is often worse at night. Symptoms may develop over days, weeks, or years. In some cases, the symptoms improve on their own and may not require advanced care. Causes of neuropathy include: diabetes physical injury (trauma) vascular and blood problems autoimmune disorders nutritional or vitamin imbalances, alcoholism, and exposure to toxins certain chemotherapy drugs infections  Most instances of neuropathy are either acquired, meaning the neuropathy isn’t present from the beginning of life, or genetic.  Acquired neuropathies are either symptomatic (the result of another disorder or condition) or idiopathic (meaning it has no known cause).

MalaCards based summary : Peripheral Nervous System Disease, also known as peripheral neuropathy, is related to autoimmune peripheral neuropathy and sensory peripheral neuropathy, and has symptoms including seizures, tremor and back pain. An important gene associated with Peripheral Nervous System Disease is NGLY1 (N-Glycanase 1), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Gabapentin and gamma-Aminobutyric acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A nervous system disease that affects the peripheral nervous system.

MedlinePlus : 43 Your peripheral nerves are the ones outside your brain and spinal cord. Like static on a telephone line, peripheral nerve disorders distort or interrupt the messages between the brain and the rest of the body. There are more than 100 kinds of peripheral nerve disorders. They can affect one nerve or many nerves. Some are the result of other diseases, like diabetic nerve problems. Others, like Guillain-Barre syndrome, happen after a virus infection. Still others are from nerve compression, like carpal tunnel syndrome or thoracic outlet syndrome. In some cases, like complex regional pain syndrome and brachial plexus injuries, the problem begins after an injury. Some people are born with peripheral nerve disorders. Symptoms often start gradually, and then get worse. They include Numbness Pain Burning or tingling Muscle weakness Sensitivity to touch Treatment aims to treat any underlying problem, reduce pain and control symptoms. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Peripheral neuropathy (PN) is damage to or disease affecting nerves, which may impair sensation,... more...

Related Diseases for Peripheral Nervous System Disease

Diseases in the Peripheral Nervous System Disease family:

Autoimmune Disease of Peripheral Nervous System

Diseases related to Peripheral Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 647)
# Related Disease Score Top Affiliating Genes
1 autoimmune peripheral neuropathy 34.3 GJB1 MAG MPZ
2 sensory peripheral neuropathy 34.2 GDAP1 GJB1 MAG MFN2 MPZ PMP22
3 motor peripheral neuropathy 34.0 GJB1 MFN2 MPZ PMP22
4 neuropathy, hereditary, with liability to pressure palsies 32.7 GDAP1 GJB1 MFN2 MPZ PMP22
5 mononeuropathy 32.6 MYOM2 PMP22 TRPV1
6 hypertrophic neuropathy of dejerine-sottas 32.6 GDAP1 GJB1 MPZ PMP22
7 polyneuropathy 32.6 GDAP1 MAG MPZ PMP22 PNPLA6 TTR
8 nerve compression syndrome 32.5 PSMD9 TTR
9 foot drop 32.4 MPZ PMP22
10 mononeuritis multiplex 32.1 MAG MYOM2
11 charcot-marie-tooth disease, x-linked dominant, 1 32.0 GJB1 MPZ PMP22
12 charcot-marie-tooth disease and deafness 31.9 GDAP1 GJB1 MFN2 MPZ PMP22
13 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 31.9 GDAP1 GJB1 MFN2 MPZ PMP22
14 charcot-marie-tooth disease, type 4a 31.8 GDAP1 TUBB3
15 nervous system disease 30.8 AQP4 INS TRPV1 TTR TUBB3
16 tooth disease 30.8 GDAP1 GJB1 MFN2 MPZ NEFL PMP22
17 charcot-marie-tooth disease 30.8 GDAP1 GJB1 MAG MFN2 MPZ NEFL
18 diabetic neuropathy 30.6 INS PMP22 TRPV1
19 carpal tunnel syndrome 30.5 INS PMP22 PSMD9 TTR
20 optic nerve disease 30.5 AQP4 MFN2 MT-ND4
21 osteosclerotic myeloma 30.4 MAG MYOM2
22 axonal neuropathy 30.2 GDAP1 MFN2 PMP22
23 neuropathy 30.2 GDAP1 GJB1 MFN2 MPZ MT-ND4 PMP22
24 neuritis 30.0 AQP4 MAG MPZ PMP22
25 demyelinating polyneuropathy 30.0 MAG PMP22 TTR
26 neuromuscular disease 30.0 MPZ MUSK PMP22
27 kearns-sayre syndrome 30.0 MAG MT-ND4 TUBB3
28 burns 29.9 INS TTR
29 neuropathy - hereditary 29.9 MPZ PMP22
30 peripheral neuropathy, myopathy, hoarseness, and hearing loss 12.5
31 mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis, and keratoderma 12.5
32 agenesis of the corpus callosum with peripheral neuropathy 12.4
33 optic atrophy, hearing loss, and peripheral neuropathy, autosomal recessive 12.3
34 peripheral neuropathy, autosomal recessive, with or without impaired intellectual development 12.3
35 cervical hypertrichosis peripheral neuropathy 12.3
36 autonomic peripheral neuropathy 12.2
37 motor neuropathy, peripheral, with dysautonomia 12.1
38 deafness, sensorineural, with peripheral neuropathy and arterial disease 12.1
39 optic atrophy, hearing loss, and peripheral neuropathy, autosomal dominant 12.1
40 spinocerebellar ataxia with rigidity and peripheral neuropathy 12.1
41 peripheral neuropathy, ataxia, focal necrotizing encephalopathy, and spongy degeneration of brain 12.1
42 deafness peripheral neuropathy arterial disease 12.1
43 autosomal dominant optic atrophy and peripheral neuropathy 12.1
44 non-progressive predominantly posterior cavitating leukoencephalopathy with peripheral neuropathy 12.1
45 neuropathy, hereditary motor and sensory, type via 11.7
46 spastic paraplegia 10, autosomal dominant 11.7
47 encephalopathy due to defective mitochondrial and peroxisomal fission 2 11.7
48 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 11.6
49 harel-yoon syndrome 11.6
50 ischemic neuropathy 11.5

Graphical network of the top 20 diseases related to Peripheral Nervous System Disease:



Diseases related to Peripheral Nervous System Disease

Symptoms & Phenotypes for Peripheral Nervous System Disease

UMLS symptoms related to Peripheral Nervous System Disease:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, neuralgia, neurologic symptoms, atypical facial pain

GenomeRNAi Phenotypes related to Peripheral Nervous System Disease according to GeneCards Suite gene sharing:

26 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.33 GJB1 MUSK
2 Decreased viability GR00106-A-0 10.33 IARS2
3 Decreased viability GR00173-A 10.33 MUSK
4 Decreased viability GR00221-A-1 10.33 MUSK
5 Decreased viability GR00221-A-4 10.33 MUSK
6 Decreased viability GR00240-S-1 10.33 MYOM2 TUBB3
7 Decreased viability GR00381-A-1 10.33 MPZ
8 Decreased viability GR00381-A-3 10.33 MPZ
9 Decreased viability GR00402-S-2 10.33 AQP4 GDAP1 GJB1 IARS2 INS MAG
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.17 IARS2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.17 IARS2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.17 PSMD9
13 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.17 IARS2 MUSK NEFL PSMD9
14 Increased shRNA abundance (Z-score > 2) GR00366-A-129 10.17 PSMD9
15 Increased shRNA abundance (Z-score > 2) GR00366-A-13 10.17 NEFL
16 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.17 NEFL
17 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.17 IARS2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.17 PSMD9
19 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.17 MUSK
20 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.17 PSMD9
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.17 NEFL
22 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.17 NEFL
23 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.17 NEFL
24 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.17 MUSK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.17 MUSK
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.17 IARS2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.17 NEFL
28 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.17 MUSK
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.17 PSMD9
30 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.17 MUSK
31 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.17 NEFL
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.17 PSMD9
33 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.17 PSMD9
34 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.17 IARS2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.17 MUSK
36 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.17 MUSK
37 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.17 PSMD9
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.17 MUSK
39 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.17 IARS2
40 no effect GR00402-S-1 9.62 AQP4 GDAP1 GJB1 IARS2 INS MAG

MGI Mouse Phenotypes related to Peripheral Nervous System Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 AQP4 GDAP1 GJB1 INS MAG MFN2
2 cellular MP:0005384 9.93 GDAP1 GJB1 INS MFN2 MPZ MUSK
3 homeostasis/metabolism MP:0005376 9.77 AQP4 GDAP1 GJB1 INS MAG MFN2
4 nervous system MP:0003631 9.47 AQP4 GDAP1 GJB1 INS MAG MFN2

Drugs & Therapeutics for Peripheral Nervous System Disease

Drugs for Peripheral Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 863)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
2
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56-12-2 119
3
Stavudine Approved, Investigational Phase 4,Phase 3 3056-17-5 18283
4
Histamine Approved, Investigational Phase 4,Phase 2,Not Applicable 51-45-6, 75614-87-8 774
5
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
6
Fexofenadine Approved, Investigational Phase 4 83799-24-0 3348
7
Imipramine Approved Phase 4 50-49-7 3696
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
9
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
10
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 378-44-9 9782
11
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
12
Etoricoxib Approved, Investigational Phase 4,Phase 2 202409-33-4 123619
13
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
14
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
15
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Not Applicable 15687-27-1 3672
16
Capsaicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 404-86-4 1548943
17
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
18
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 13422-55-4
19
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
20
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
21
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-42-6 5284603
22
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
23
Nabilone Approved, Investigational Phase 4,Phase 3,Phase 2 51022-71-0 5284592
24
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
25
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
26
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
27
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 175805 71273
28
Levobupivacaine Approved, Investigational Phase 4,Phase 3,Not Applicable 27262-47-1 92253
29
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
30
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
31
Nortriptyline Approved Phase 4,Phase 2,Not Applicable 72-69-5 4543
32
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2921-57-5
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
34
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
35
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
36
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 302-25-0
37
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
38
Amitriptyline Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-48-6 2160
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
40
Minocycline Approved, Investigational Phase 4,Phase 2,Not Applicable 10118-90-8 5281021
41
Perphenazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-39-9 4748
42
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
43
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 298-46-4 2554
44
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
45 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
47
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2 1972-08-3 16078
48
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 64-17-5 702
49
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
50
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3

Interventional clinical trials:

(show top 50) (show all 2638)
# Name Status NCT ID Phase Drugs
1 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
2 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
3 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
4 Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY Unknown status NCT00235222 Phase 4 stavudine
5 Pregabalin for the Treatment of Uremic Pruritus Unknown status NCT01852318 Phase 4 pregabalin 75mg daily for 12 weeks;fexofenadine 60 mg daily for 12 weeks;placebo
6 A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy Unknown status NCT01875562 Phase 4 Qishe Pill
7 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
8 Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain Unknown status NCT02846701 Phase 4 duloxetine
9 Transforaminal Epidural Steroid Injection With Pulsed Radiofrequency for Chronic Lumbosacral Radicular Pain Management Unknown status NCT02930057 Phase 4 Celestone;Control
10 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
11 Duration of Antibiotic Therapy in Community - Acquired Pneumonia Unknown status NCT01492387 Phase 4
12 Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy Unknown status NCT02414698 Phase 4 TESI
13 Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy Unknown status NCT01204008 Phase 4
14 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
15 Preventing Pain After Heart Surgery Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
16 Ultrasound-guided Caudal or Interlaminar Corticosteroid Epidural Injection for Sciatica Unknown status NCT02897336 Phase 4
17 Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Sciatica Presented to the Emergency Department Unknown status NCT02777320 Phase 4 paracetamol;Ibuprofen
18 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
19 IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia Unknown status NCT02504996 Phase 4 Paracetamol;morphine;Placebo
20 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
21 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
22 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
23 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
24 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
25 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
26 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
27 Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159731 Phase 4 Pregabalin
28 Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus Completed NCT03031834 Phase 4 Quinapril
29 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Completed NCT00380913 Phase 4 Cesamet™ (nabilone)
30 Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Completed NCT00159679 Phase 4 Pregabalin
31 A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN) Completed NCT00156078 Phase 4 pregabalin
32 A Study of the Efficacy and Safety of Pregabalin for the Treatment of Diabetic Peripheral Neuropathy or Postherpetic Neuralgia Completed NCT00629681 Phase 4 Pregabalin
33 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management Completed NCT01364298 Phase 4 Gabapentin/B-complex;Pregabalin
34 Intrathecal Bolus Doses of Ziconotide Completed NCT01373983 Phase 4 Ziconotide
35 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP Completed NCT00407511 Phase 4 Pregabalin
36 Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
37 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
38 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
39 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
40 Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
41 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
42 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo
43 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
44 Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component Completed NCT01166048 Phase 4 Duloxetine;Duloxetine
45 An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus) Completed NCT00194909 Phase 4 sildenafil (Viagra)
46 Effect of Arginine on Microcirculation in Patients With Diabetes Completed NCT00902616 Phase 4
47 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy Completed NCT02056366 Phase 4 α-lipoic acid
48 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
49 Pharmacokinetics and Optimal Timing of Dronedarone Initiation Following Long-term Amiodarone in Patients With Paroxysmal or Persistent Atrial Fibrillation Completed NCT01199081 Phase 4 Dronedarone
50 CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo

Search NIH Clinical Center for Peripheral Nervous System Disease

Cochrane evidence based reviews: peripheral nervous system diseases

Genetic Tests for Peripheral Nervous System Disease

Genetic tests related to Peripheral Nervous System Disease:

# Genetic test Affiliating Genes
1 Peripheral Neuropathy 29

Anatomical Context for Peripheral Nervous System Disease

MalaCards organs/tissues related to Peripheral Nervous System Disease:

41
Brain, Spinal Cord, Testes, Skin, Lung, Bone, Colon

Publications for Peripheral Nervous System Disease

Articles related to Peripheral Nervous System Disease:

(show top 50) (show all 2022)
# Title Authors Year
1
Differences in skin blood flow oscillations between the plantar and dorsal foot in people with diabetes mellitus and peripheral neuropathy. ( 30414870 )
2019
2
Vasculitis and peripheral neuropathy. ( 30461543 )
2019
3
Response to Crevenna and Ashbury, Vallance and Bolam, and Crevenna and Keilani regarding the effects of exercise on chemotherapy-induced peripheral neuropathy. ( 30374766 )
2019
4
Letter to the editor-comments on Kleckner et al. (2018) "Effects of exercise during chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial". ( 30032400 )
2019
5
Chemotherapy-induced peripheral neuropathy-more high-quality research is needed. ( 30046880 )
2019
6
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. ( 28954297 )
2018
7
Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. ( 28954296 )
2018
8
Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort. ( 29439162 )
2018
9
Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation. ( 29981335 )
2018
10
[EXPRESS] TRPA1 sensitization during diabetic vascular impairment contributes to cold hypersensitivity in a mouse model of painful diabetic peripheral neuropathy. ( 29968518 )
2018
11
Correlation between serum vitamin B12 level and peripheral neuropathy in atrophic gastritis. ( 29599609 )
2018
12
Identification of IFRD1 variant in a Han Chinese family with autosomal dominant hereditary spastic paraplegia associated with peripheral neuropathy and ataxia. ( 29362493 )
2018
13
Effect of diverse physical rehabilitative interventions on static postural control in diabetic peripheral neuropathy: a systematic review. ( 29979897 )
2018
14
Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. ( 29963528 )
2018
15
AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). ( 29316812 )
2018
16
Ergothioneine ameliorates oxaliplatin-induced peripheral neuropathy in rats. ( 29981320 )
2018
17
Fasudil combined with methylcobalamin or lipoic acid can improve the nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis. ( 29979431 )
2018
18
Peripheral neuropathy in Tangier disease: A literature review and assessment. ( 29582519 )
2018
19
Evoked and Ongoing Pain-Like Behaviours in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. ( 29973969 )
2018
20
Kikuchi's disease (histiocytic necrotizing lymphadenitis): A rare presentation with acute kidney injury, peripheral neuropathy, and aseptic meningitis with cutaneous involvement. ( 29567898 )
2018
21
Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. ( 29235198 )
2018
22
MR neurography biomarkers to characterize peripheral neuropathy in AL amyloidosis. ( 30030328 )
2018
23
Role of miR-9-5p in preventing peripheral neuropathy in patients with rheumatoid arthritis by targeting REST/miR-132 pathway. ( 30456455 )
2018
24
Prevalence of Charcot Arthropathy in Type 2 Diabetes Patients Aged over 50 Years with Severe Peripheral Neuropathy: A Retrospective Study in a Tertiary Care South Indian Hospital. ( 29535947 )
2018
25
Effector/memory CD8+ T cells synergize with co-stimulation competent macrophages to trigger autoimmune peripheral neuropathy. ( 29627532 )
2018
26
Assessment of Peripheral Neuropathy in Patients with β-Thalassemia via Electrophysiological Study: Reevaluation in the Era of Iron Chelators. ( 30200834 )
2018
27
BDNF Val66Met is Associated with Pre-existing but not with Paclitaxel-induced Peripheral Neuropathy in an Israeli Cohort of Breast Cancer Patients. ( 30550003 )
2018
28
Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Trial. ( 30420895 )
2018
29
Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. ( 30426838 )
2018
30
Carpal tunnel syndrome: just a peripheral neuropathy? ( 29869575 )
2018
31
Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. ( 30119132 )
2018
32
LINEZOLID-INDUCED MITOCHONDRIAL TOXICITY PRESENTING AS RETINAL NERVE FIBER LAYER MICROCYSTS AND OPTIC AND PERIPHERAL NEUROPATHY IN A PATIENT WITH CHRONIC GRANULOMATOUS DISEASE. ( 30048406 )
2018
33
Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis. ( 30526124 )
2018
34
Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer. ( 30536809 )
2018
35
Creutzfeldt-Jakob disease with unusual presentation of peripheral neuropathy and ophthalmoplegia. ( 30319957 )
2018
36
Prion-related peripheral neuropathy in sporadic Creutzfeldt-Jakob disease. ( 30355606 )
2018
37
Serum 25(OH) vitamin D level and its relation to diabetic peripheral neuropathy in Egyptian patients with type 2 diabetes mellitus. ( 30532515 )
2018
38
The Necessity of the Simple Tests for Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus Patients without Neuropathic Symptoms in Clinical Practice. ( 30362305 )
2018
39
The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. ( 30321183 )
2018
40
Low serum phosphate and magnesium levels are associated with peripheral neuropathy in patients with type 2 diabetes mellitus. ( 30273706 )
2018
41
The potential of transdermal nitric oxide treatment for diabetic peripheral neuropathy and diabetic foot ulcers. ( 30030157 )
2018
42
An exercise program for people with severe peripheral neuropathy and diabetic foot ulcers - a case series on feasibility and safety. ( 30293458 )
2018
43
Efficiencies of Low-Level Laser Therapy (LLLT) and Gabapentin in the Management of Peripheral Neuropathy: Diabetic Neuropathy. ( 29527628 )
2018
44
A "Triple Trouble" Case of Facioscapulohumeral Muscular Dystrophy Accompanied by Peripheral Neuropathy and Myoclonic Epilepsy. ( 30203790 )
2018
45
Hyperglycemia-induced Bcl-2/Bax-mediated apoptosis of Schwann cells via mTORC1/S6K1 inhibition in diabetic peripheral neuropathy. ( 29621478 )
2018
46
Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats. ( 29750001 )
2018
47
Hypoxia-inducible factor 1α protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species. ( 30361814 )
2018
48
Adult-onset Leigh syndrome with central fever and peripheral neuropathy due to mitochondrial 9176T>C mutation. ( 30136164 )
2018
49
Genetic Variants Associated with Vincristine-Induced Peripheral Neuropathy in Two Populations of Children with Acute Lymphoblastic Leukemia. ( 30506673 )
2018
50
Large granular lymphocytic leukemia-associated peripheral neuropathy. ( 29568991 )
2018

Variations for Peripheral Nervous System Disease

ClinVar genetic disease variations for Peripheral Nervous System Disease:

6 (show top 50) (show all 125)
# Gene Variation Type Significance SNP ID Assembly Location
1 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 GRCh37 Chromosome 16, 3293403: 3293403
2 MEFV NM_000243.2(MEFV): c.2084A> G (p.Lys695Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs104895094 GRCh38 Chromosome 16, 3243403: 3243403
3 ABCA4 NM_000350.2(ABCA4): c.2588G> C (p.Gly863Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs76157638 GRCh37 Chromosome 1, 94517254: 94517254
4 ABCA4 NM_000350.2(ABCA4): c.2588G> C (p.Gly863Ala) single nucleotide variant Conflicting interpretations of pathogenicity rs76157638 GRCh38 Chromosome 1, 94051698: 94051698
5 NEFL NM_006158.4(NEFL): c.64C> T (p.Pro22Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28928910 GRCh37 Chromosome 8, 24813966: 24813966
6 NEFL NM_006158.4(NEFL): c.64C> T (p.Pro22Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28928910 GRCh38 Chromosome 8, 24956452: 24956452
7 ABCA4 NM_000350.2(ABCA4): c.203C> T (p.Pro68Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs62654397 GRCh37 Chromosome 1, 94577093: 94577093
8 ABCA4 NM_000350.2(ABCA4): c.203C> T (p.Pro68Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs62654397 GRCh38 Chromosome 1, 94111537: 94111537
9 DNM2 NM_001005360.2(DNM2): c.190G> A (p.Val64Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs144250390 GRCh37 Chromosome 19, 10870442: 10870442
10 DNM2 NM_001005360.2(DNM2): c.190G> A (p.Val64Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs144250390 GRCh38 Chromosome 19, 10759766: 10759766
11 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh38 Chromosome 1, 220143109: 220143109
12 IARS2 NM_018060.3(IARS2): c.2726C> T (p.Pro909Leu) single nucleotide variant Pathogenic rs587783070 GRCh37 Chromosome 1, 220316451: 220316451
13 LMNA NM_170707.3(LMNA): c.1634G> A (p.Arg545His) single nucleotide variant Conflicting interpretations of pathogenicity rs142191737 GRCh37 Chromosome 1, 156107470: 156107470